Sarepta therapeutics director sells $205,399 in inventory

CAMBRIDGE, MA—Kathryn Jean Boor, a director at Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a $12.3 billion biotech firm with a “GOOD” InvestingPro Monetary Well being rating, has bought 1,636 shares of widespread inventory, in response to a current SEC submitting. The shares had been bought at a value of $125.55 every, amounting to a complete transaction worth of $205,399. Following this transaction, Boor retains possession of 5,880 shares within the firm. The sale was performed to generate money for tax funds associated to the vesting of restricted inventory unit awards. The corporate’s inventory, which has delivered a forty five% return over the previous yr, at the moment trades close to $128, with 5 analysts lately revising earnings estimates upward. For deeper insights into insider buying and selling patterns and complete evaluation, entry the complete InvestingPro Analysis Report, out there for over 1,400 US shares.

In different current information, Sarepta Therapeutics has seen a flurry of exercise with important monetary implications. The corporate’s inventory goal was trimmed by H.C. Wainwright to $75, whereas sustaining a promote score. This adjustment comes within the wake of Sarepta’s licensing take care of Arrowhead Prescription drugs (NASDAQ:ARWR), which contains a wide range of scientific and preclinical belongings.

Sarepta’s partnership with Arrowhead is predicted to boost its analysis and growth capabilities, including doubtlessly 13 RNAi packages to its pipeline. The settlement features a $500 million upfront cost, a $325 million fairness funding in Arrowhead, and an extra $250 million over the subsequent 5 years.

Analyst rankings from varied companies, together with BMO Capital, Piper Sandler, Needham, and Morgan Stanley (NYSE:MS), have maintained constructive outlooks on Sarepta’s inventory. These companies have highlighted the strategic worth of the Arrowhead deal and Sarepta’s introduced share repurchase program as proof of its sturdy place.

Regardless of the constructive rankings, some analysts have expressed warning, citing the necessity for compelling scientific proof earlier than incorporating the brand new packages into their valuation mannequin. Sarepta’s administration has reaffirmed its expectation to stay money stream constructive, signaling a wholesome monetary state.

These current developments are a part of a broader sample of strategic strikes by Sarepta, which is predicted to steer the corporate to profitability and constructive money stream. Nevertheless, the effectiveness of RNAi therapeutics in tissues aside from the liver stays to be confirmed, as no scientific information from the licensed packages is at the moment out there.

This text was generated with the help of AI and reviewed by an editor. For extra data see our T&C.